Alain J. Delmer

Reims, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 96 publications

Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group.

Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group.

Journal: EClinicalMedicine

Published: July 30, 2025

Autologous and Allogeneic Stem-Cell Transplantation for Transformed Waldenström Macroglobulinemia.

Autologous and Allogeneic Stem-Cell Transplantation for Transformed Waldenström Macroglobulinemia.

Journal: American journal of hematology

Published: September 04, 2024

Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia.

Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 24, 2024

High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia.

High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia.

Journal: Blood

Published: February 27, 2024

Evaluation and Management of Disease Transformation in Waldenström Macroglobulinemia.

Evaluation and Management of Disease Transformation in Waldenström Macroglobulinemia.

Journal: Hematology/oncology clinics of North America

Published: May 28, 2023

Pretreatment CT Texture Parameters as Predictive Biomarkers of Progression-Free Survival in Follicular Lymphoma Treated with Immunochemotherapy and Rituximab Maintenance.

Pretreatment CT Texture Parameters as Predictive Biomarkers of Progression-Free Survival in Follicular Lymphoma Treated with Immunochemotherapy and Rituximab Maintenance.

Journal: Diagnostics (Basel, Switzerland)

Published: May 03, 2023

Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial.

Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 25, 2023

Born in the UK: A registry to improve and broadcast knowledge on Waldenström macroglobulinaemia.

Born in the UK: A registry to improve and broadcast knowledge on Waldenström macroglobulinaemia.

Journal: British journal of haematology

Published: February 01, 2023

First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia.

First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia.

Journal: Leukemia research

Published: December 21, 2022

A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial.

A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial.

Journal: Blood advances

Published: December 20, 2022

Risk Factors of Progression in Low-tumor Burden Follicular Lymphoma Initially Managed by Watch and Wait in the Era of PET and Rituximab.

Risk Factors of Progression in Low-tumor Burden Follicular Lymphoma Initially Managed by Watch and Wait in the Era of PET and Rituximab.

Journal: HemaSphere

Published: October 04, 2022

Retrospective analysis of a cohort of 41 de novo B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study).

Retrospective analysis of a cohort of 41 de novo B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study).

Journal: Haematologica

Published: September 26, 2022

Showing 1-12 of 96

Last Updated: 09/26/2026